HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.

Abstract
A new adjuvant therapy, individual adjuvant therapy (IAT), which is individualized according to the results of real-time reverse-transcription polymerase chain-reaction (RT-PCR) for O6-methylguanine-DNA methyltransferase (MGMT), was used to treat malignant gliomas. Immediately after the operation, mRNA expression for drug-resistance genes was investigated in frozen samples of malignant gliomas from 55 patients (30 glioblastoma multiformes, 20 anaplastic astrocytomas and 5 anaplastic oligodendroglial tumors) by real-time quantitative RT-PCR with specific primers for MGMT. Forty-two patients were treated with 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU)-based chemotherapies since the relative quantitation value (RQV) of MGMT in real-time RT-PCR with SYBR-Green I was <1.0 or the absolute value of MGMT mRNA as measured by Taq Man probe methods normalized to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was <6.0x10(3) copies/microg RNA. Thirteen patients, whose tumors had an RQV of >1.0 or who had an absolute value of MGMT of >6.0x10(3) copies/microg RNA, were treated by platinum-based chemotherapy using cisplatin or carboplatin. The response rate was 40.9% for glioblastoma multiformes, 60.0% for anaplastic astrocytomas and 80.0% for anaplastic oligodendroglial tumors. The median survival period of 30 patients with glioblastoma treated by IAT was 21.7 months. The 2-year survival rate of glioblastoma patients treated by IAT was 70.9%. Our IAT, based on the results of real-time RT-PCR, may lead to a beneficial glioma therapy.
AuthorsSatoshi Tanaka, Jiro Akimoto, Ikuo Kobayashi, Hidehiro Oka, Hiroshi Ujiie
JournalOncology reports (Oncol Rep) Vol. 20 Issue 1 Pg. 165-71 (Jul 2008) ISSN: 1021-335X [Print] Greece
PMID18575733 (Publication Type: Journal Article)
Chemical References
  • RNA, Messenger
  • Dacarbazine
  • O(6)-Methylguanine-DNA Methyltransferase
  • Temozolomide
Topics
  • Adult
  • Brain Neoplasms (mortality, therapy)
  • Combined Modality Therapy
  • Dacarbazine (analogs & derivatives, therapeutic use)
  • Evidence-Based Medicine
  • Female
  • Glioma (mortality, therapy)
  • Humans
  • Male
  • Middle Aged
  • O(6)-Methylguanine-DNA Methyltransferase (genetics)
  • RNA, Messenger (analysis)
  • Reverse Transcriptase Polymerase Chain Reaction (methods)
  • Survival Rate
  • Temozolomide

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: